Boehringer Accelerates Adalimumab Dual Pricing Strategy With 81% Discount
Adds Deep-Discounted Unbranded Version Of Cyltezo Biosimilar Rival To Humira In The US
Boehringer Ingelheim says it is pushing ahead with an earlier than expected launch of a deep-discounted unbranded version of its Cyltezo adalimumab biosimilar in the US, as it looks to compete with other Humira rivals.
You may also be interested in...
With several Humira biosimilars entering the US market, price competition was fiercer and faster than expected in the second half of 2023, according to Cencora. The former AmerisourceBergen firm’s biosimilars experts Brian Biehn and Connor Nell touch on topics including adalimumab trends, ophthalmology and oncology biosimilars, and the Inflation Reduction Act in a Q&A with Generics Bulletin.
The launch of competition to Humira was the main event for US biosimilars this year – but a number of other key developments also took place in 2023, including settlements on Stelara that set up a series of launches in 2025, as well as first approvals for ustekinumab, natalizumab and tocilizumab biosimilars.
The FDA recently approved a second US Humira biosimilar, from Pfizer, as interchangeable – just a few months after the launch of Boehringer Ingelheim’s interchangeable Cyltezo – despite first interchangeable biosimilars benefiting from a year of exclusivity. Now, the agency has shed further light on the decision in response to Generics Bulletin queries.